开立医疗：一季度实现营收4.3亿元

Group 1 - The company reported a revenue of 430 million yuan and a net profit of 8.07 million yuan for Q1 2025, with a non-recurring net profit of 5.9981 million yuan [1] - R&D investment for Q1 2025 reached 126 million yuan, representing a year-on-year increase of 23.7% [1] - The company is focusing on integrating medical technology with clinical applications, leveraging "medical devices + AI" to drive smart development [1] Group 2 - The company has launched several key products, including the 4K iEndo smart endoscope platform, which has received NMPA registration and is now in the promotion phase [1] - The iEndo platform features an independent GPU module that enhances image processing and AI computing capabilities, introducing a new super-resolution imaging technology for clearer clinical diagnostics [1] - In the minimally invasive surgery sector, the "Lingzhu" 4K 3D fluorescence imaging platform has been certified, offering a comprehensive solution that combines various imaging technologies [2] Group 3 - The company aims to maintain its competitive edge by continuously innovating and advancing its product lines towards high-end and specialized markets [2] - With the recovery of the domestic medical device market in 2025, the company is increasing its market share in ultrasound and endoscopy, while its strategic layout in minimally invasive surgery and cardiovascular intervention products is maturing [2] - The company is expected to return to a growth trajectory, developing a comprehensive multi-product line strategy that includes "internal medicine + surgery," "diagnosis + treatment," and "equipment + consumables" [2]